9. Teva—$135M

Teva
Teva opted to settle with the state of Illinois claims it inflated wholesale prices to defraud the state's Medicaid system. (Teva)

Company: Teva
Settlement amount: $135 million
Date: January 2019
Claims: Medicaid fraud
Plaintiff: State of Illinois
Product: Various drugs

In recent years, Teva has been no stranger to big legal overhangs with national opioid suits and "pay-for-delay" allegations on the docket. But entering 2019, Teva got one lawsuit off the books when it settled with the state of Illinois on a Medicaid pricing fraud case.

In January, Teva agreed to pay $135 million to wrap up allegations that it and 46 other drugmakers fraudulently published inflated average wholesale prices that went into calculating Medicaid reimbursement rates. As a result, taxpayers overpaid for Teva drugs, the 2005 state suit argued.

After the deal was inked, state Attorney General Lisa Madigan flaunted the yield from that suit: The state had recovered more than $436 million in settlements from various companies, according to her office.

RELATED: Teva shells out $135M to wrap Illinois AG's Medicaid pricing fraud suit

The settlement helped Teva put one challenge in the rearview mirror as it continues to face an industrywide generics price-fixing probe, a potential multibillion-dollar overhang in its opioid litigation and an ongoing $3 billion cost-cutting drive. 

In October, Teva offered a whopping $23 billion "framework" deal to settle the thousands of opioid suits it faces. As part of the deal, the drugmaker would donate buprenorphine naloxone, an opioid addiction treatment, worth a list value of $23 billion over the next 10 years. The combined $23.25 billion deal far outshoots a similar global opioid offer from Purdue Pharma reportedly valued at up to $12 billion.

9. Teva—$135M

Suggested Articles

A number of high-dollar settlements could be coming as drugmakers look to bail on opioid suits. Will they top the largest deals in the last two years?

Since 2015, female representation in the C-suite has grown from 17% to 21%. But many women are held back by a “broken rung” in the corporate ladder.

Pharma companies are breaking out with smart creative, innovative tools and tech-assisted novelties that go beyond standard drug advertising fare.